BLU-667 exhibits durable activity in RET-altered thyroid cancer
June 03, 2019
A HemOncToday article outlines results for a thyroid cancer clinical trial led by Matthew Taylor, M.D. “It’s exciting to see that this is such a relevant molecular target, and that it can be targeted with a highly selective specific drug that doesn’t cause as many off-target side effects as the other drugs in the market,” says Taylor.